Last reviewed · How we verify
efavirenz (drug)
efavirenz (drug) is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) Small molecule drug developed by French National Agency for Research on AIDS and Viral Hepatitis. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by binding to the reverse transcriptase enzyme, preventing the replication of retroviruses such as HIV.
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by binding to the reverse transcriptase enzyme, preventing the replication of retroviruses such as HIV. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | efavirenz (drug) |
|---|---|
| Sponsor | French National Agency for Research on AIDS and Viral Hepatitis |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Efavirenz is a potent inhibitor of the HIV-1 reverse transcriptase enzyme, which is essential for the replication of the virus. By binding to the enzyme, efavirenz prevents the conversion of viral RNA into DNA, thereby inhibiting viral replication. This mechanism of action is specific to retroviruses such as HIV.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of mother-to-child transmission of HIV
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
- Insomnia
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Efavirenz for the Treatment of Creutzfeldt-Jakob Disease (PHASE3)
- The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY (NA)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK (EARLY_PHASE1)
- A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants (PHASE1)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- efavirenz (drug) CI brief — competitive landscape report
- efavirenz (drug) updates RSS · CI watch RSS
- French National Agency for Research on AIDS and Viral Hepatitis portfolio CI
Frequently asked questions about efavirenz (drug)
What is efavirenz (drug)?
How does efavirenz (drug) work?
What is efavirenz (drug) used for?
Who makes efavirenz (drug)?
What drug class is efavirenz (drug) in?
What development phase is efavirenz (drug) in?
What are the side effects of efavirenz (drug)?
What does efavirenz (drug) target?
Related
- Drug class: All Non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs
- Target: All drugs targeting HIV-1 reverse transcriptase
- Manufacturer: French National Agency for Research on AIDS and Viral Hepatitis — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Treatment of HIV-1 infection in adults and children
- Indication: Drugs for Prevention of mother-to-child transmission of HIV